Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
Manchester Management Accuses Vermillion of Changing Meeting Date to Discourage Shareholder Action
April 29, 2011
Manchester Management's James Besser this week sent a letter to the company's board and shareholders asserting that management had moved the date of Vermillion's annual meeting to make difficult any action by shareholders dissatisfied by the poor performance of the firm's stock.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- Citing Falling Share Price, Manchester Management Calls for Changes to Vermillion Leadership
April 22, 2011 / ProteoMonitor - Vermillion Posts $431K in Q1 Revenue, Anticipates Two Peer-Reviewed Articles on OVA1
May 13, 2011 / ProteoMonitor - Vermillion Shareholder Alleges Medicare Denying Over 80 Percent of OVA1 Reimbursement Claims
December 23, 2011 / ProteoMonitor - Vermillion Performs 3,920 OVA1 Tests in Q2, But Revenues Fall 9 Percent on Drop in Licensing Income
August 5, 2011 / ProteoMonitor - Vermillion Announces Patent for AD Biomarkers, Second Peer-Reviewed Paper on OVA1
May 27, 2011 / ProteoMonitor